Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up

Neurology

Volumn 37, Issue 5, 1987, Pages 826-828

  Rinne, U K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; BROMOCRIPTINE; LEVODOPA;

ADVERSE DRUG REACTION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CONFUSION; DRUG DOSE; DRUG EFFICACY; DRUG MIXTURE; DRUG THERAPY; DYSKINESIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; NAUSEA; NERVOUS SYSTEM; NEUROTOXICITY; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PLEURISY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESPIRATORY SYSTEM; THERAPY; VOMITING;

BROMOCRIPTINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMAN; LEVODOPA; PARKINSON DISEASE;

EID: 0023225016     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.37.5.826     Document Type: Article

References (24)

1. Rinne UK. Problems associated with long-term levdopa treatment of Parkinson’s diseaee. Acta Neurol Scand 1983;68(suppl 95):19–26.
2. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 1986;35:1196–1198.
3. Calne DB, Teychenne PF, Claveria LJ, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br Med J 1974;4:442–444.
4. Parkes JD, Marsden CD, Donaldson I. Bromocriptine treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1976;39:184–193.
5. Fahn S, Cote U, Snider SR, Barrett RE, Iagreen WP. The role of bromocriptine in the treatment of parkinsonism. Neurology 1979;29:1077–1083.
6. Rinne UK. Recent advances in the treatment of Parkinson’s disease. Acta New1 Scand 1980;62:103–121.
7. Lieberman AN, Goldskin M. Treatment of advanad Parkinson’s disease with dopamine agoniets. In: Maraden CD, Fahn S, eds. Movement dieorders. London: Butterworth, 1982:146–165.
8. Rinne UK. New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horoweki R, McDonald RJ, Wuttke W, eds. Liwvide and other dopamine agoniete. New York: Raven Prees, 1983:431–442.
9. Hoehn MM. Result of chronic levodopa therapy and ita modification by bromocriptine in Parkinson’s disease. Acta Neurol Scand 1985;71:97–106.
10. Rinne UK, Marttila R. Brain dopamine receptor stimulation and the relief of parkinsonism: relationship between bromocriptine and levodopa. Ann Neurol 1978;4:263–267.
11. less AJ, Stem GM. Sustained bromocriptine therapy in previouely untreated patienta with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1981;44:1020–1023.
12. Teychenne PF, Bergerud D, Racy A, Elton RL, Vern B. Bromocriptine: low dose therapy in Parkinson’s disease. Neurology 1982;32:577–583.
13. Rinne UK. Dopamine agonieta in the treatment of Parkinson’s disease. Adv Neuro1 1983;37:141–150.
14. Grimes JD, Deigado MR, Gray P. Low dose bromocriptine therapy in “de novo” Parkinson’s disease: indications, dosage, initial reaponae rate and adverse effects. Neurology 1983,33(suppl 2):112.
15. Raecol A, Montastruc JL, Rascol D. Should dopamine agonieta be given early or late in the treatment of Parkinson’s disease? Can J Neurol Sci 1984;11:229–232.
16. Staal-Schreinemachers AL, Weaseling H, Kamphuis DJ, v.d. Burg W, Lakke JPWF. Low-dose bromocriptine therapy in Parkinson’s diaease: double-blind, placebo-controlled study. Neurology 1986;36:291–293.
17. Ogawa N, Yamawaki Y, Kuroda H, Nukina I, Ofuji T. Effects of long-term administration of levodopa and bromocriptine on rat striatal dopamine receptors. International Congress Series. Amsterdam: Excerpta Medica, 1981;548:351.
18. Carhn A. Are “on-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm 1983;19:153–161.
19. Lenders K, Palmer A, Turton D, Firnau G, Jones T, Maraden D. Human cerebral dopamine pathway visualized in vivo. J Neurol 1985;232(suppl):9.
20. Nutt JG, Woodward WR, Hammerstad JP. The “on-oft” phenomenon in Parkinson’s disease: relation to levodopa abeorption and transport. N End J Med 1984;310:483–488.
21. Quinn N, Parkes JD, Maraden CD. Control of on-off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131–1136.
22. Quinn N, Marsden CD, Schachter M, Thompson C, Lang AE, Parkes JD. Intmvenow buride in extrapyramidal disorders. In: Calne DB, Hod R, McDonald RJ, Wuttke W, eds. Lieuride and other dopamine agonists. New York: Raven Reas, 1983:383–393.
23. Rinne UK. New devebpmenta and expectations for the future in the tmatment of Parkinson’s diaease. In: Birkmayer W, Rinne UK, Worm-Petersen J, Dupont E, Schwarz W, eds. Parkinson’s disease: current problem and management. Basel: Editiones Roche, 1985:79–88.
24. Obeeo JA, Luquin MR, Martinez-Lage JM. Lieuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s diseaee. Lancet 1986;1:467–470.